Background: The induction of hematopoietic stem cells to produce mass numbers of platelets (PLTs) in vitro is an effective method to address a lack of PLTs and PLT transfusion resistance in the clinic. However, the design of a low-cost and sustainable culture system is currently problematic.

Study Design And Methods: Here, the thrombopoietin, interleukin (IL)-6, and IL-11 genes, three regulatory factors important for thrombopoiesis, were used to construct self-splicing fusion genes linked by foot and mouth disease (F2A) and Theiler's murine encephalitis (T2A) viruses. Bone marrow stromal cells (BMSCs) transduced with the fusion gene acted as nourishing cells and induced cord blood mononuclear cells (MNCs) to generate PLTs in vitro. We counted these cells; determined the percentage of cells expressing specific cell surface markers (CD41); and measured their ability to aggregate via flow cytometry, immunohistochemical staining, and aggregation remote analyzer.

Results: BMSCs transduced with the fusion gene successfully induced cord blood MNCs to generate PLT-sized fragments in the absence of exogenous cytokines. The output was higher than that of the control groups, and the PLT-sized fragments were similar to endogenous PLTs in terms of shape, CD41 expression, and aggregation function.

Conclusion: These results suggest that our method could be used to develop a low-cost sustainable cultivation system that generates PLTs in vitro by enhancing the autocrine production of related cytokines through the nourishment provided by cells transduced with a syncretic gene.

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.12800DOI Listing

Publication Analysis

Top Keywords

plts vitro
12
cells
9
bone marrow
8
marrow stromal
8
stromal cells
8
cells transduced
8
syncretic gene
8
mononuclear cells
8
low-cost sustainable
8
bmscs transduced
8

Similar Publications

Background: Pathogen reduction (PR) may be used as an alternative to gamma or x-ray irradiation (I) to prevent transfusion associated graft versus host disease (TA-GVHD) if the pathogen reduction technology has been shown to inactivate residual lymphocytes. However, as I is considered the gold standard for reducing the risk of TA-GVHD, some centers continue to perform I in addition to PR. This study investigated the effect of concurrent pathogen reduction and irradiation (PR/I) on the biochemical characteristics of apheresis platelets at day 1, 5, and 7 of storage at room temperature.

View Article and Find Full Text PDF

Background: Splitting apheresis platelet (PLT) units increase available inventory during shortages. The impact of prolonged storage in gas-impermeable aliquot bags on PLT quality in vitro and transfusion outcomes in patients remains uncertain.

Study Design And Methods: We assessed in vitro PLT quality and thromboelastography (TEG) in PLTs stored for 8 or 24 h in aliquot bags compared with baseline (T0).

View Article and Find Full Text PDF

A Novel Engineering Cell Therapy Platform Mimicking the Immune Thrombocytopenia-Derived Platelets to Inhibit Cytokine Storm in Hemophagocytic Lymphohistiocytosis.

Adv Sci (Weinh)

December 2024

Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, China.

Article Synopsis
  • Hemophagocytic lymphohistiocytosis (HLH) is a severe inflammatory condition with no specific treatments, caused by abnormal activation of macrophages.
  • Researchers have developed a new targeted therapy called anti-CD41-PLT-VP16, which combines engineered platelets and a drug (VP16) that induces macrophage death, showing effective results in both lab and live models.
  • Early clinical trials indicate that this innovative therapy significantly improves patient outcomes, tripling the response rate compared to standard treatments for HLH.
View Article and Find Full Text PDF

Optimizing the delivery and penetration of nano-sized drugs within liver cancer sites, along with remodeling the tumor microenvironment, is crucial for enhancing the efficacy of chemotherapeutic agents. For this study, a platelet (PLT)-mediated nanodrug delivery system (DASA+ATO@PLT) was developed to improve the effectiveness of chemotherapy. This system delivers nano-sized dasatinib and atovaquone specifically to liver tumor sites and facilitates intra-tumoral permeation upon release.

View Article and Find Full Text PDF

Background: Hepatocellular carcinoma (HCC) is the most common malignant liver disease in the world. Platelets (PLTs) are known to play a key role in the maintenance of liver homeostasis and the pathophysiological processes of a variety of liver diseases. Aspirin is the most classic antiplatelet agent.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!